The Use of Digoxin in Patients With Worsening Chronic Heart Failure
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Digoxin is the oldest cardiac drug still in contemporary use, yet its role in the management of patients with heart failure (HF) remains controversial. A purified cardiac glycoside derived from the foxglove plant, digoxin increases ejection fraction, augments cardiac output, and reduces pulmonary capillary wedge pressure without causing deleterious increases in heart rate or decreases in blood pressure. Moreover, it is also a neurohormonal modulator at low doses. In the pivotal DIG (Digitalis Investigation Group) trial, digoxin therapy was shown to reduce all-cause and HF-specific hospitalizations but had no effect on survival. With the discovery of neurohormonal blockers capable of reducing mortality in HF with reduced ejection fraction, the results of the DIG trial were viewed as neutral, and the use of digoxin declined precipitously. Although modern drug and device-based therapies have dramatically improved the survival of ambulatory patients with HF, outcomes for patients with worsening chronic HF, defined as deteriorating signs and symptoms on standard therapy often leading to unscheduled clinic or emergency department visits or hospitalization, have largely remained unchanged over the past 2 decades. The available data suggest that a therapeutic trial of digoxin may be appropriate in patients with worsening chronic heart failure who remain symptomatic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016 · cited 2×
“Despite safety concerns regarding supratherapeutic levels and fatal arrhythmias, the absolute incidence of digoxin toxicity requiring hospitalization is low both in the controlled setting of a study (6) and in the context of routine clinical practice (66,67).”
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 1×
“Ivabradine selectively inhibits the pacemaker I f current, slowing the HR by approximately 10 beats/min and thereby reducing CV morbidity and mortality (56 – 58).”
Ahmed, A., Rich, M. W., Fleg, J. L., Zile, M. R., Young, J. B., Kitzman, D. W., Love, T. E., Aronow, W. S., Adams, K. F., & Gheorghiade, M. (2006) · Circulation · doi:10.1161/circulationaha.106.628347 · Cited by 605
Self-citationIncreased mortality among patients taking digoxin—analysis from the AFFIRM study
Whitbeck, M. G., Charnigo, R. J., Khairy, P., Ziada, K., Bailey, A. L., Zegarra, M. M., Shah, J., Morales, G., Macaulay, T., Sorrell, V. L., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs348 · Cited by 279
Khand, A. U., Rankin, A. C., Martin, W., Taylor, J., Gemmell, I., & Cleland, J. G. F. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.020 · Cited by 271 · cited 1×
“Similarly, additional research should be conducted in the 30% to 40% of patients with HF with comorbid atrial fi brillation in whom the combination of carvedilol and digoxin has been shown to improve rate control, left ventricular EF, and symptomatology compared with either agent alone (70).”
Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0467-8 · Cited by 248 · cited 1×
“Ivabradine selectively inhibits the pacemaker I f current, slowing the HR by approximately 10 beats/min and thereby reducing CV morbidity and mortality (56 – 58).”
Gheorghiade, M., Fonarow, G. C., van Veldhuisen, D. J., Cleland, J. G. F., Butler, J., Epstein, A. E., Patel, K., Aban, I. B., Aronow, W. S., Anker, S. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht120 · Cited by 192
Self-citationClinical notes on the illness and death of President Franklin D. Roosevelt
BRUENN, H. G. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-4-579 · Cited by 84
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
The vulnerable phase after hospitalization for heart failure
Greene, S. J., Fonarow, G. C., Vaduganathan, M., Khan, S. S., Butler, J., & Gheorghiade, M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.14 · Cited by 406
Self-citation
Metadata
- Authors
- Ambrosy, A. P., Butler, J., Ahmed, A., Vaduganathan, M., van Veldhuisen, D. J., Colucci, W. S., & Gheorghiade, M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 63
- Issue
- 18
- Pages
- 1823-1832
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2157824210
- Cited by
- 99
- References
- 9
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.